Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,164 Cr
Revenue (TTM)
₹700 Cr
Net Profit (TTM)
₹76 Cr
ROE
8.6 %
ROCE
13.2 %
P/E Ratio
15.2
P/B Ratio
1.9
Industry P/E
28.4
EV/EBITDA
8.8
Div. Yield
0 %
Debt to Equity
0
Book Value
₹463.7
EPS
₹57.1
Face value
10
Shares outstanding
13,366,988
CFO
₹593.22 Cr
EBITDA
₹543.74 Cr
Net Profit
₹118.21 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Venus Remedies
| 13.3 | 12.6 | 13.2 | 193.9 | 76.2 | 26.2 | 25.0 |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Venus Remedies
| 140.6 | -21.4 | 124.3 | -55.7 | 147.5 | 587.2 | -49.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Venus Remedies
|
868.3 | 1,163.6 | 699.9 | 76.3 | 12.0 | 13.2 | 15.2 | 1.9 |
| 2,904.7 | 37,130.9 | 5,201.6 | 1,014.6 | 22.9 | 25 | 36.6 | 8.1 | |
| 8,321.0 | 20,755.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 103.3 | 25.0 | |
| 1,604.1 | 12,230.3 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.9 | 3.7 | |
| 1,284.9 | 17,969.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 41.6 | 5.0 | |
| 2,138.6 | 34,607.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.9 | 8.6 | |
| 4,773.5 | 21,779.6 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.5 | 5.5 | |
| 4,860.6 | 8,091.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.6 | 11.6 | |
| 3,386.1 | 7,784.4 | 1,837.4 | 326.7 | 24.7 | 45.3 | 23.8 | 10.4 | |
| 903.7 | 8,388.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.4 | 2.8 |
2 min read•By Research Desk
2 min read•By Research Desk
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic... and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India. Read more
Incorporated
1989
Chairman
Pawan Chaudhary
Managing Director
Pawan Chaudhary
Headquarters
Chandigarh, Union Territory
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Venus Remedies Ltd is ₹868.25 (NSE) and ₹867.05 (BSE) as of 20-Mar-2026 IST. Venus Remedies Ltd has given a return of 76.23% in the last 3 years.
The P/E ratio of Venus Remedies Ltd is 15.25 times as on 20-Mar-2026, a 46 discount to its peers’ median range of 28.40 times.
The P/B ratio of Venus Remedies Ltd is 1.88 times as on 20-Mar-2026, a 58 discount to its peers’ median range of 4.48 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
8.84
|
0.71
|
|
2024
|
15.31
|
0.89
|
|
2023
|
8.15
|
0.47
|
|
2022
|
8.82
|
0.82
|
|
2021
|
5.49
|
0.88
|
The 52-week high and low of Venus Remedies Ltd are Rs 944.75 and Rs 277.95 as of 20-Mar-2026.
Venus Remedies Ltd has a market capitalisation of ₹ 1,164 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Venus Remedies Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹12.85
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.